NO20074149L - Nye farmasoytiske sammensetninger for behandling av trombose - Google Patents

Nye farmasoytiske sammensetninger for behandling av trombose

Info

Publication number
NO20074149L
NO20074149L NO20074149A NO20074149A NO20074149L NO 20074149 L NO20074149 L NO 20074149L NO 20074149 A NO20074149 A NO 20074149A NO 20074149 A NO20074149 A NO 20074149A NO 20074149 L NO20074149 L NO 20074149L
Authority
NO
Norway
Prior art keywords
antagonists
inhibitors
thrombosis
treatment
pharmaceutical compositions
Prior art date
Application number
NO20074149A
Other languages
English (en)
Norwegian (no)
Inventor
James C Gilbert
Paul A Reilly
Thomas H Mueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36423564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074149(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20074149L publication Critical patent/NO20074149L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20074149A 2005-03-29 2007-08-10 Nye farmasoytiske sammensetninger for behandling av trombose NO20074149L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05006711 2005-03-29
PCT/EP2006/061046 WO2006103206A2 (en) 2005-03-29 2006-03-27 Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis

Publications (1)

Publication Number Publication Date
NO20074149L true NO20074149L (no) 2007-12-11

Family

ID=36423564

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074149A NO20074149L (no) 2005-03-29 2007-08-10 Nye farmasoytiske sammensetninger for behandling av trombose

Country Status (19)

Country Link
US (2) US20060222640A1 (https=)
EP (1) EP1885354A2 (https=)
JP (1) JP2008534552A (https=)
KR (1) KR20070116936A (https=)
CN (1) CN101151030A (https=)
AR (1) AR056291A1 (https=)
AU (1) AU2006228600A1 (https=)
BR (1) BRPI0608656A2 (https=)
CA (1) CA2602563A1 (https=)
CL (1) CL2010000395A1 (https=)
EA (1) EA015122B1 (https=)
IL (1) IL186267A0 (https=)
MX (1) MX2007010664A (https=)
NO (1) NO20074149L (https=)
NZ (1) NZ562775A (https=)
TW (1) TW200722089A (https=)
UA (1) UA92603C2 (https=)
WO (1) WO2006103206A2 (https=)
ZA (1) ZA200706698B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
IL159273A0 (en) * 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US20080274166A1 (en) * 2005-06-10 2008-11-06 Transpharma Medical Ltd. Patch for Transdermal Drug Delivery
AR062057A1 (es) * 2006-07-17 2008-10-15 Boehringer Ingelheim Int Uso de los inhibidores directos de la trombina
WO2008043759A1 (en) * 2006-10-10 2008-04-17 Boehringer Ingelheim International Gmbh Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
CA2704164A1 (en) * 2007-10-29 2009-05-07 Transpharma Medical Ltd. Vertical patch drying
WO2010013231A2 (en) * 2008-07-29 2010-02-04 Yeda Research And Development Co. Ltd. Modulation of coagulation factors and effectors of same for control of transplant organ size
WO2010029552A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
JP2013510072A (ja) 2008-11-11 2013-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法
CN102209546A (zh) * 2008-11-11 2011-10-05 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法
AR074108A1 (es) * 2008-11-11 2010-12-22 Boehringer Ingelheim Int Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina
RU2011132125A (ru) 2008-12-30 2013-02-10 Тромбологик Апс Способы идентификации критических пациентов с повышенным риском развития органной недостаточности и соединения для их лечения
JP6012629B2 (ja) * 2011-01-25 2016-10-25 ユニヴェルシテ カソリック ド ルーヴァンＵｎｉｖｅｒｓｉｔｅ Ｃａｔｈｏｌｉｑｕｅ Ｄｅ Ｌｏｕｖａｉｎ 細胞移植のための組成物および方法
CN102250099B (zh) * 2011-05-16 2013-10-16 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
EP2806879B1 (en) 2012-01-25 2019-03-06 Université Catholique de Louvain Compositions and methods for cell transplantation
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
EP2722033A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
EP2722034B1 (en) * 2012-10-19 2020-09-16 Sanovel Ilac Sanayi ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
ES2759228T3 (es) 2013-07-05 2020-05-08 Univ Catholique Louvain Medio acondicionado de células madre de hígado de adultos y su uso en el tratamiento de trastornos del hígado
DE102014108210A1 (de) * 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
CN108236612A (zh) * 2016-12-27 2018-07-03 李志忠 用于冠脉介入手术中抗凝的组合产品及其用途
US12251377B2 (en) 2019-03-06 2025-03-18 University Of Rochester Anticoagulant compositions and uses thereof
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use
CN115192691B (zh) * 2022-08-31 2025-03-04 晓恩医药包装材料(安庆)有限公司 一种阿加曲班注射液及预灌封注射器

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
NZ286082A (en) * 1995-03-15 1998-09-24 Behringwerke Ag Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9930540D0 (en) * 1999-12-23 2000-02-16 Rhone Poulenc Rorer Pharma Chemical compounds
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
KR20040044514A (ko) * 2001-09-14 2004-05-28 미쯔비시 웰 파마 가부시키가이샤 항혈전약과 피라졸론 유도체의 조합 약제
KR101005716B1 (ko) * 2002-03-07 2011-01-05 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2004231306A1 (en) * 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors

Also Published As

Publication number Publication date
WO2006103206A2 (en) 2006-10-05
US20100184729A1 (en) 2010-07-22
IL186267A0 (en) 2008-01-20
CL2010000395A1 (es) 2010-08-20
JP2008534552A (ja) 2008-08-28
WO2006103206A3 (en) 2007-01-11
BRPI0608656A2 (pt) 2010-01-19
US20060222640A1 (en) 2006-10-05
TW200722089A (en) 2007-06-16
CN101151030A (zh) 2008-03-26
NZ562775A (en) 2011-03-31
EA015122B1 (ru) 2011-06-30
KR20070116936A (ko) 2007-12-11
MX2007010664A (es) 2007-12-12
EA200701841A1 (ru) 2008-02-28
AR056291A1 (es) 2007-10-03
EP1885354A2 (en) 2008-02-13
UA92603C2 (ru) 2010-11-25
AU2006228600A1 (en) 2006-10-05
CA2602563A1 (en) 2006-10-05
ZA200706698B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
NO20074149L (no) Nye farmasoytiske sammensetninger for behandling av trombose
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
AR071523A1 (es) Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
JOP20220085A1 (ar) مركبات أريل ميثيلين حلقية غير متجانسة على هيئة حاصرات قناة بوتاسيوم Kv1.3 بجين شاكر
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
CO5580771A2 (es) Antagonistas ccr5 como agentes terapeuticos
WO2008065500A3 (en) Heteroaryl amides as type i glycine transport inhibitors
MEP11708A (en) Dimethoxy docetaxel acetone solvate et method for the preparation thereof
CL2008003691A1 (es) Compuestos derivados de 4-(fenil o piridin) pirimidina, inhibidores de la elastasa neutrofila humana; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o la prevencion de hipertension arterial pulmonar, epoc, enfisema pulmonar, entre otras.
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
DE602008002934D1 (de) 2-cyclopropylthiazolderivate
SE0302760D0 (sv) New compounds
NO20045120L (no) Triazolderivater som takykininreseptorantagonister
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
ECSP078052A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
NO20060202L (no) Pyrrolodihydroisokinoliner som PDE-10-inhibitorer
NO20062483L (no) 5-(benz-(z)-yliden)-tiazolidin-4-onderivater som immunundertrykkende midler
ECSP078051A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
NO20085212L (no) Nye pyridinanaloger
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
BRPI0713132B8 (pt) compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos
NO20064160L (no) Nye azaibicykliske forbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application